ARQT

Arcutis Biotherapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 8/10
  • Value↓ 1/10
Arcutis Biotherapeutics sales and earnings growth
ARQT Growth
Good
  • Revenue Y/Y↑ 86.80%
  • EPS Y/Y↑ 97.09%
  • FCF Y/Y↑ 124.10%
Arcutis Biotherapeutics gross and profit margin trends
ARQT Profitability
Good
  • Gross margin ↑ 90.90%
  • EPS margin↓ -0.60%
  • ROIC 5Y↓ -32.52%
Arcutis Biotherapeutics net debt vs free cash flow
ARQT Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↓ 3.0
  • Interest coverage↓ 0.9

Arcutis Biotherapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks